BioScience Health Innovations (BHIC) EBIAT (2020 - 2025)
BioScience Health Innovations (BHIC) has disclosed EBIAT for 6 consecutive years, with -$233630.0 as the latest value for Q4 2025.
- Quarterly EBIAT fell 2446.39% to -$233630.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $642090.0 through Dec 2025, up 638.03% year-over-year, with the annual reading at $642090.0 for FY2025, 638.03% up from the prior year.
- EBIAT for Q4 2025 was -$233630.0 at BioScience Health Innovations, down from -$8782.0 in the prior quarter.
- The five-year high for EBIAT was $457704.0 in Q2 2025, with the low at -$233630.0 in Q4 2025.
- Average EBIAT over 5 years is $17271.6, with a median of -$13378.5 recorded in 2021.
- Peak annual rise in EBIAT hit 899.53% in 2025, while the deepest fall reached 2446.39% in 2025.
- Over 5 years, EBIAT stood at -$14089.0 in 2021, then plummeted by 105.25% to -$28917.0 in 2022, then tumbled by 32.71% to -$38376.0 in 2023, then soared by 125.95% to $9957.0 in 2024, then crashed by 2446.39% to -$233630.0 in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$233630.0, -$8782.0, and $457704.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.